New prognostic factors in nasopharyngeal carcinoma: Tumor angiogenesis and c-erbB2 expression

Cancer

Volumn 77, Issue 8, 1996, Pages 1419-1426

  Roychowdhury, Debasish F ^a,c,d   Tseng Jr , Alexander ^a   Fu, Karen K ^a   Weinberg, Vivian ^b   Weidner, Noel ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

c erbB2; immunohistochemistry; nasopharyngeal carcinoma; prognostic factors; tumor angiogenesis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY KI 67; PROTEIN P53;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CERVICAL LYMPH NODE; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 0029915849     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960415)77:8<1419::AID-CNCR1>3.0.CO;2-7     Document Type: Article

References (38)

1. Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 1994;21:382-97.
2. Neel BH, Taylor WF, Pearson GR. Prognostic determinants and a new view of staging for patients with nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol 1985;94:529-37.
3. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol 1993;10:302-13.
4. Van der Zee AGJ, Hollema H, Suurmeijer AJH, Krans M, Sluiter WJ, Willemse PHB, et al. Value of p-glycoprotein, glutathione s-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995;13:70-8.
5. Craven JM, Pavelic Z, Stambrook PJ, Pavelic L, Gapany M, Kelley DJ, et al. Expression of c-erbB-2 gene in head and neck carcinoma. Anticancer Res 1992;12:2273-6.
6. Field JK, Spandidos DA, Yiagnisis M, Gosney JR, Papadimitriou K, Stell PM. C-erb-B-2 expression in squamous cell carcinoma of the head and neck. Anticancer Res 1992; 12:613-20.
7. Gaspirini G, Boracchi P, Bevilacqua P, Mezetti M, Pozza F, Weidner N. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma. Breast Cancer Treat 1994;29:59-71.
8. Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, et al. Prognostic significance of the Ki-67 associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994;83:1460-6.
9. Gaspirini G, Weidner N, Maluta S, Pozza F, Boracchi P, Mezzetti M, et al. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer 1993;55:739-44.
10. Histological typing of upper respiratory tract tumors. In: World Health Organization. International histological classification of tumors, No 19. Geneva, Switzerland: World Health Organization, 1978:32-3.
11. Weidner N, Semple JP, Welch W, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
12. Weidner N. The relationship of tumor angiogenesis and metastasis with emphasis on invasive breast carcinoma. In: Advances in pathology and laboratory medicine. Volume 5. Chicago: Mosby-Yearbook, 1992:101-22.
13. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allerd EN, Moore DH, et al. Tumor angiogenesis: a significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
14. McCormick D, Chong H, Hobbs C, Datta C, Hall PA. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology 1993;22:355-60.
15. 2 from contingency tables and the calculation of P. J Royal Statist Soc 1922;85:87-94.
16. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of diseases. J Natl Cancer Inst 1959;22:719-48.
18. Cox DR. Regression models and life table (with discussion). J R Stat Society Ser B 1972;34:187-220.
19. Dawson-Saunders B, Trapp RG. Summarizing data. In: Basic & Clinical Biostatistics. Norwalk: Appleton & Lange, 1994:52-3.
20. Folkman J. What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 1990;82:4-6.
21. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267: 10931-4.
22. Liotta L, Kleinerman J, Saldel G. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastasis following tumor implantation. Cancer Res 1974; 34:997-1004.
23. 2 and histological appearance in human cervix carcinoma [abstract P25-384]. Proc Radiation Res Soc 1995;200.
24. Hartmann LC, Ingle JN, Wold LE, Farr GH Jr, Grill JP, Su JQ, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 1994;74:2956-63.
25. Volm M, Efferth T, Mattern J. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res 1992;12:11-20.
26. Oka K, Nakano T, Arai T. C-erbB-2 oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer 1994;73:668-71.
27. Harpole DH Jr, Herndon JE 2nd, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression. Cancer Res 1995; 55:51-6.
28. Lee EY, Cibull ML, Strodel WE, Haley JV. Expression of HER-2/neu overexpression and epidermal growth factor receptor and prognosis in gastric carcinoma. Arch Pathol Lab Med 1994;118:235-9.
29. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
30. Press MF, Pike MI, Hung G, Zhou JY, Ma Y, George J, et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 1994;54:5675-82.
31. Nakamura T, Nekarda H, Hoelscher AH. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of the Barrett's esophagus. Cancer 1994;73:1785-94.
32. Perez CA, Devineni VR, Marcial-Vega V, Marks JE, Simpson JR, Kucik N, et al. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys 1992; 23:271-80.
33. Grandi C, Boracchi P, Mezzanotte G, Squadrelli M, Marubini E, Molinari R. Analysis of prognostic factors and proposal of a new classification for nasopharyngeal cancer. Head Neck 1990;12:31-40.
34. Tytor M, Olofsson J. Prognostic factors in oral cavity carcinomas. Acta Otolaryngol (Stockh) 1992;492(Suppl):75-8.
35. Auclair PL, Goode RK, Ellis GL. Mucoepidermoid carcinoma of intraoral salivary glands. Cancer 1992;69:2021-30.
36. Bicknell R. Vascular targetting and the inhibition of angiogenesis. Ann Oncol 1994;5(4 Suppl):45-50.
37. Baselga J, Tripathy D, Mendelsohn J, Benz C, Dantis L, Moore J, et al. Phase II study of recombinant human anti-HER2 monoclonal antibody in stage IV breast cancer, [abstract 113]. Proc Am Soc Clin 1995;14:103.
38. Feng BC, Dai YR, Xiao ZD. A morphological study of stromal microvasculature of nasopharyngeal precancerous lesions. Chin Med J (Engl) 1991;104:422-4.